IP Library Granted Patent US 12,256,935
Granted Patent B2
US 12,256,935 · App. 17/054,283 · Granted Mar 25, 2025

Controlling rate of blood flow to right atrium

Inventor: Michael Gabriel Tal (Tel Aviv, IL)
Assignee: VENACORE INC.
A61B17/12036A61B17/12109A61B17/12168A61B17/12186A61B2017/00862A61F2002/068A61F2230/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,256,935
App. No.
17/054,283
Granted
Mar 25, 2025
Kind
B2
Abstract

Blood flow affecting implant and implantation thereof in superior vena cava, optionally including disintegration of endothelium layer and inducing tissue ingrowth within implant. Implant includes elongated body with optional tubular inner layer forming orifice, shapeable to final orifice diameter for restricting blood flowing therethrough to chosen average flow rate; and/or tubular outer layer provided coaxially around inner layer. Outer layer is formed of second material provided in elastically deformable state for facilitating elastic radial self¬expanding from collapsed diameter up to relaxed maximal expanded diameter greater than diameter of inner wall portion of superior vena cava. Inner layer is formed of first material, in plastically or elastically deformable state.

Claims (29)

1. A method for affecting rate of blood flow entering a right atrium in a heart of a subject, the method comprising:

disintegrating an endothelium layer in a chosen target wall portion of a superior vena cava opened to the right atrium by removing and/or damaging some or all of the endothelium layer in the target wall portion of the superior vena cava;

after the disintegrating, anchoring a blood flow affecting implant to said target wall portion, said implant comprising a tubular implant body having an implant proximal portion, an implant distal portion, and an implant intermediate portion provided between said implant proximal and distal portions, said implant intermediate portion is shaped with a narrowing and comprises a plurality of openings for allowing blood flow passage across said narrowing; and

wherein the disintegrating is sufficient for inducing stenosis and/or tissue remodeling of the superior vena cava at said target wall portion, sufficiently for gradually occupying a space formed between said narrowing and said target wall portion with naturally occurring tissue ingrowth until effecting blocking of said blood flow from passing across said narrowing.

2. The method according to claim 1 , wherein said anchoring results with said narrowing being shaped to surround an orifice having a final orifice diameter configured for restricting blood flowing through said orifice to a chosen average flow rate, when said space is filled with said tissue ingrowth sufficiently to block said blood flow from passing across said narrowing.

3. The method according to claim 1 , wherein said anchoring results with said narrowing being shaped to cover an entire cross section of a superior vena cava lumen occupied by said implant body, thereby completely blocking blood flow through said implant intermediate portion when said space is filled with said tissue ingrowth sufficiently to block said blood flow from passing across said narrowing.

4. The method according to claim 1 , wherein said proximal implant portion descends in diameter in a proximal-to-distal direction and/or said distal implant portion ascends in diameter in a proximal-to-distal direction.

5. The method according to claim 1 , wherein said implant body includes a tubular inner layer forming said narrowing, and a tubular outer layer provided coaxially around said inner layer and configured for anchoring the implant to said target wall portion.

6. The method according to claim 5 , wherein said inner layer is formed of a first material provided in a plastically deformable state for facilitating selective radial changeability in diameter of said narrowing between a plurality of fixed diameters.

7. The method according to claim 5 , wherein said inner layer is formed of a first material provided in an elastically deformable state for facilitating self-expansion from a predetermined initial orifice diameter to said final orifice diameter of said orifice.

8. The method according to claim 5 , wherein said inner layer and/or said outer layer includes a mesh, a wire, peripheral slits or struts.

9. The method according to claim 5 , wherein the disintegrating is performed by rotating the outer layer against the blood vessel.

10. The method according to claim 1 , wherein said inducing further comprises providing a tissue growth inducing agent in or around said space.

11. The method according to claim 10 , wherein said tissue growth inducing agent comprises growth factors.

12. A method comprising:

disintegrating an endothelium layer in a chosen target wall portion of a blood vessel by removing and/or damaging some or all of the endothelium layer in the target wall portion of the blood vessel;

after the disintegrating, anchoring a blood flow affecting implant to said target wall portion, said blood flow affecting implant comprising an implant body having a narrowing and a plurality of openings for allowing blood flow passage across said narrowing; and

wherein the disintegrating is sufficient for inducing stenosis and/or tissue remodeling of the blood vessel at said target wall portion, sufficiently for gradually occupying a space formed between said narrowing and said target wall tissue with naturally occurring tissue ingrowth until effecting blocking of said blood flow from passing across said narrowing.

13. The method according to claim 12 , wherein said anchoring results with said narrowing being shaped to surround an orifice having a final orifice diameter configured for restricting blood flowing through said orifice to a chosen average flow rate, when said space is filled with said tissue ingrowth sufficiently to block said blood flow from passing across said narrowing.

14. The method according to claim 12 , wherein said anchoring results with said narrowing being shaped to cover an entire cross section of a blood vessel lumen occupied by said implant body, thereby completely blocking blood flow therethrough when said space is filled with said tissue ingrowth sufficiently to block said blood flow from passing across said narrowing.

15. The method according to claim 12 , wherein said implant comprises a tubular implant body having an implant proximal portion, an implant distal portion, and an implant intermediate portion provided between said implant proximal and distal portions, and wherein said implant intermediate portion is shaped with a narrowing and comprises a plurality of openings for allowing blood flow passage across said narrowing.

16. The method according to claim 15 , wherein said proximal implant portion descends in diameter in a proximal-to-distal direction and/or said distal implant portion ascends in diameter in a proximal-to-distal direction.

17. The method according to claim 12 , wherein said implant body includes a tubular inner layer forming said narrowing, and a tubular outer layer provided coaxially around said inner layer and configured for anchoring the implant to said target wall portion.

18. The method according to claim 17 , wherein the disintegrating is performed by rotating the outer layer against the blood vessel.

19. The method according to claim 17 , wherein said inner layer is formed of a first material provided in a plastically deformable state for facilitating selective radial changeability in diameter of said narrowing between a plurality of fixed diameters.

20. The method according to claim 17 , wherein said inner layer is formed of a first material provided in an elastically deformable state for facilitating self-expansion from a predetermined initial orifice diameter to said final orifice diameter of said orifice.

21. The method according to claim 17 , wherein said inner layer and/or said outer layer includes a mesh, a wire, peripheral slits or struts.

22. The method according to claim 12 , wherein said inducing further comprises providing a tissue growth inducing agent in or around said space.

23. The method according to claim 22 , wherein said tissue growth inducing agent comprises growth factors.

Assignments (2)
CHANGE OF NAME Recorded May 26, 2026
From: VENACORE, INC.
To: TOTAL MEDICAL INC.
Reel/Frame 074757/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2021
From: TAL, MICHAEL GABRIEL
To: VENACORE INC.
Reel/Frame 056473/0406 →
Continuity (2)
Provisional Application 62670728 · May 12, 2018
Related Publication 20210177426A1 · Jun 17, 2021
References Cited (61)
US 5383926A · Lock et al. · 1995 [cited by applicant]
US 5824046A · Smith et al. · 1998 [cited by applicant]
US 5954765A · Ruiz · 1999 [cited by applicant]
US 6336937B1 · Vonesh et al. · 2002 [cited by applicant]
US 6350277B1 · Kocur · 2002 [cited by applicant]
US 6419686B1 · McLeod et al. · 2002 [cited by applicant]
US 6638293B1 · Makower et al. · 2003 [cited by applicant]
US 6878160B2 · Gilligan et al. · 2005 [cited by applicant]
US 6953476B1 · Shalev · 2005 [cited by applicant]
US 7159593B2 · McCarthy et al. · 2007 [cited by applicant]
US 7530995B2 · Quijano et al. · 2009 [cited by applicant]
US 8105344B2 · Yeung et al. · 2012 [cited by applicant]
US 8425584B2 · Cully et al. · 2013 [cited by applicant]
US 8556954B2 · Muvhar et al. · 2013 [cited by applicant]
US 8621975B2 · Russo et al. · 2014 [cited by applicant]
US 8858612B2 · Ben-Muvhar et al. · 2014 [cited by applicant]
US 8906057B2 · Connor et al. · 2014 [cited by applicant]
US 8911489B2 · Ben-Muvhar · 2014 [cited by applicant]
US 8923973B2 · Gross · 2014 [cited by applicant]
US 9107743B2 · Iancea et al. · 2015 [cited by applicant]
US 9364354B2 · Ben-Muvhar et al. · 2016 [cited by applicant]
US 9393384B1 · Kapur · 2016 [cited by examiner]
US 9402634B2 · Russo et al. · 2016 [cited by applicant]
US 9681876B2 · Cragg et al. · 2017 [cited by applicant]
US 9707124B2 · Brenzel et al. · 2017 [cited by applicant]
US 9744059B2 · Ben-Muvhar · 2017 [cited by applicant]
US 9848883B2 · Cragg et al. · 2017 [cited by applicant]
US 10010328B2 · Cragg et al. · 2018 [cited by applicant]
US 10178995B2 · Cragg et al. · 2019 [cited by applicant]
US 10548606B2 · Hui et al. · 2020 [cited by applicant]
US 20020045931A1 · Sogard et al. · 2002 [cited by applicant]
US 20030065386A1 · Weadock · 2003 [cited by applicant]
US 20040230288A1 · Rosenthal · 2004 [cited by applicant]
US 20050055082A1 · Ben Muvhar · 2005 [cited by examiner]
US 20050064009A1 · Bates · 2005 [cited by applicant]
US 20060106449A1 · Muvhar · 2006 [cited by applicant]
US 20060106450A1 · Muvhar · 2006 [cited by applicant]
US 20060116627A1 · Bridges et al. · 2006 [cited by applicant]
US 20110152998A1 · Berez · 2011 [cited by examiner]
US 20120316597A1 · Fitz et al. · 2012 [cited by applicant]
US 20140052103A1 · Cully et al. · 2014 [cited by applicant]
US 20140121759A1 · Cully · 2014 [cited by applicant]
US 20150173919A1 · Baldwin · 2015 [cited by applicant]
US 20150282958A1 · Centola et al. · 2015 [cited by applicant]
US 20160256169A1 · Ben-Muvhar et al. · 2016 [cited by applicant]
US 20170086854A1 · Cragg et al. · 2017 [cited by applicant]
US 20170165059A1 · Roselli et al. · 2017 [cited by applicant]
US 20170172771A1 · Bruckheimer et al. · 2017 [cited by applicant]
US 20180085128A1 · Bellomo et al. · 2018 [cited by applicant]
US 20180280167A1 · Folan · 2018 [cited by examiner]
US 20180303639A1 · Ben-Muvhar · 2018 [cited by applicant]
US 20190126014A1 · Kapur et al. · 2019 [cited by applicant]
US 20190133601A1 · Cragg et al. · 2019 [cited by applicant]
US 20190239998A1 · Tuval · 2019 [cited by examiner]
US 20190255302A1 · Kapur et al. · 2019 [cited by applicant]
US 20190307459A1 · Celermajer · 2019 [cited by examiner]
US 20190314551A1 · Matheny · 2019 [cited by examiner]
WO 2017062740A1 · 2017 [cited by applicant]
WO 2018197983A1 · 2018 [cited by applicant]
WO 2018225059A1 · 2018 [cited by applicant]
WO 2019083989A1 · 2019 [cited by applicant]